Published in Medicine and Law Weekly, March 17th, 2006
Study findings also show that Cymbalta did not adversely affect the progression of diabetes or many of the complications associated with the illness, such as damage to the nerves, kidneys and eyes.
The findings, published in the Journal of Palliative Medicine, "suggest that with Cymbalta, clinicians can expect a similar level of quality of life without compromising safety or tolerability," said Tim Smith, a study...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly